June 15, 2026 a 09:00 pm
DGX: Analysts Ratings - Quest Diagnostics Incorporated
Quest Diagnostics, a key player in the diagnostic sector, continues to garner attention from analysts. Recent analyst ratings reflect a consensus towards stable performance, with a predominant number of recommendations categorized as 'Hold' and 'Buy'. While there is a noticeable support for 'Strong Buy', the majority of analyst sentiment remains moderate, indicating an expectation of consistency in the company's market position.
Historical Stock Grades
| Rating | Count | Score |
|---|---|---|
| Strong Buy | 2 | |
| Buy | 7 | |
| Hold | 9 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
The sentiment analysis over several months reveals a stable inclination towards moderate recommendations with 'Hold' and 'Buy' prevailing. There is a consistent number of 'Strong Buy' ratings, yet no significant uptick in 'Sell' recommendations. Overall, a steady sentiment with no dramatic shifts can be observed.
- April to June 2026: Consistent ratings with minor shifts in 'Hold' positions.
- 2025 Observations: Minor reduction in 'Strong Buy', indicating caution or stabilization in outlook.
Percentage Trends
Analyzing the percentage shifts in analyst recommendations shows a subtle yet notable shift towards 'Hold' sentiments over the past year while recommendations for 'Strong Buy' remain minimal. This suggests an increase in market caution and a balanced perspective on the company's performance potential.
- 2026: 'Hold' dominates with 45% of ratings, indicating market reservations.
- 2019-2026: Incremental rise in 'Hold' recommendations mirrors increased analyst caution.
Latest Analyst Recommendations
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-04-22 | Overweight | Overweight | Barclays |
| 2026-04-22 | Neutral | Neutral | Baird |
| 2026-04-22 | Neutral | Neutral | UBS |
| 2026-04-22 | Hold | Hold | Truist Securities |
| 2026-04-08 | In Line | In Line | Evercore ISI Group |
Analyst Recommendations with Change of Opinion
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2025-08-25 | Neutral | Outperform | Baird |
| 2025-03-04 | Neutral | Buy | Citigroup |
| 2025-01-06 | Outperform | Market Perform | Leerink Partners |
| 2024-12-17 | Overweight | Equal Weight | Morgan Stanley |
| 2024-10-23 | Outperform | Neutral | Baird |
Interpretation
From the analysis, it can be inferred that analysts maintain a cautiously optimistic stance towards Quest Diagnostics. The consistency in 'Hold' and 'Buy' recommendations suggests stability, although the minimal presence of 'Strong Buy' ratings indicates restrained expectations for rapid growth. There is no pressing indication of increased instability or volatility, signifying a stable yet cautious market perception.
Conclusion
Quest Diagnostics encapsulates a stable investment opportunity with inherent resilience in its business model. Analysts exhibit a cautious optimism reflected in the dominant 'Hold' and 'Buy' recommendations, suggesting expected market consistency. The restrained but steady outlook, combined with static sentiment trends, implies a balanced risk-to-reward scenario for potential investors.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years